Single-Dose Rifampicin Prophylaxis for Leprosy Contacts: Aligning with Antimicrobial Stewardship Principles
Pugazhenthan Thangaraju*
JASPI March 2026 / Volume 4 /Issue 1
Copyright: © Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
January – March 31, 2026
Thangaraju P, Single-Dose Rifampicin Prophylaxis for Leprosy Contacts: Aligning with Antimicrobial Stewardship Principles. JASPI. 2026;4(1):Page No
DOI: 10.62541/jaspi094
Dear Editor,
Despite notable declines in prevalence over the past few decades, leprosy remains a public health concern. In 2024, the World Health Organisation (WHO) reported over 172,717 new cases worldwide, with South East Asia 124 295 and India bearing about 100957 of the burden 1. In addition to achieving elimination objectives, creative approaches are needed to ensure that interventions align with broader public health principles, such as antimicrobial stewardship (AMS). One such measure recommended by WHO in its Global Leprosy Strategy is single-dose rifampicin (SDR, 600mg) chemoprophylaxis for contacts of leprosy patients 2, 3.
Submit a Manuscript:
Copyright © Author(s) 2026. JASPI- Journal of Antimicrobial Stewardship Practices and Infectious Diseases.